Important note

This AI stock analysis for Adaptimmune Therapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Adaptimmune Therapeutics - AI Stock Analysis

Analysis generated October 22, 2025

Adaptimmune Therapeutics is a biopharmaceutical company focused on developing novel cancer immunotherapy treatments. The company uses its proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell technology to target and combat specific cancer cells effectively. Adaptimmune's pipeline includes multiple clinical-stage programs aimed at various cancers, providing innovative therapeutic options for patients with limited treatments.

Fundamental Analysis

Adaptimmune Therapeutics has shown mixed results in terms of its recent financial performance. The revenue for the last quarter was $14M, reflecting an increase of 87.74% compared to the previous quarter. This growth quarter-over-quarter is a positive sign, but when compared to the same quarter last year, there is a significant decrease of 89.33%, which raises concerns about long-term revenue stability.

The net income for the last quarter was $30M, an increase of 36.24% compared to the quarter before it. However, compared to the same quarter last year, the net income decreased by 143.64%. While the quarter-over-quarter growth is promising, the year-over-year decline is concerning.

EBITDA for the last quarter was $0, marking a 100.00% increase compared to the previous quarter. However, like the net income and revenue, the EBITDA has seen a 100.00% decrease compared to the same quarter last year. This trend suggests the company might be struggling with profitability in the long run.

Recently, several company insiders have been selling their stock, which can be viewed as a bearish signal. Insider selling might indicate a lack of confidence in the company's future prospects.

Technical Analysis

The current stock price of Adaptimmune Therapeutics is $0.07. This represents a decrease of 58.82% compared to a month ago and a significant drop of 91.03% compared to a year ago. This dramatic decline in stock price indicates substantial bearish sentiment in both the short and long term.

The company is currently in a bearish trend. The SMA10 is $0.15, slightly lower than the previous SMA10 of $0.16, suggesting a potential downward trend in price movement. The Relative Strength Index (RSI) stands at 61.9, indicating a neutral condition, which does not confirm any imminent reversal of the bearish trend.

Alternative Data Analysis

Alternative data insights show mixed signals for Adaptimmune Therapeutics. Website traffic, a useful gauge for customer interest and engagement, has increased by 200% in the last few months, reaching an estimated 21,000 visitors. This uptick in web traffic might indicate growing interest from potential customers or investors, a bullish signal.

However, when considering AltIndex's AI score, which combines fundamental, technical, and alternative data to predict stock price performance, Adaptimmune Therapeutics has a score of 47. This score implies a 'Hold' recommendation, indicating neither a strong buying nor selling signal at this time.

Conclusion and Recommendation

Adaptimmune Therapeutics presents a complex investment opportunity with mixed signals across various analyses. The company shows quarter-over-quarter growth in revenue and net income, although the year-over-year figures are concerning. The technical analysis depicts a distinctly bearish trend in its stock price, exacerbated by clear downward movement indicators. Increased web traffic offers a glimmer of optimism for future prospects, while the AltIndex AI score suggests a 'Hold' status.

Given these factors, it's recommended to exercise caution with Adaptimmune Therapeutics stock. Monitoring future quarters' financial performance, insider trading activities, and overarching market conditions is crucial to make a well-informed investment decision.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.